MedTrace Logo

Safety of ALK Ragweed Tablet

NCT00330083 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2007-09-21

No results posted yet for this study

Summary

This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults

Conditions

  • Allergy

Interventions

BIOLOGICAL

ALK Ragweed Tablet

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • George J. Atiee, MD · Healthcare Discoveries Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330083 on ClinicalTrials.gov